Drugs / Pyronaridine
Pyronaridine
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07470424 | Jun 2026 → Jun 2027 expected | malaria | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05287893 | Apr → Sep 2022 | Plasmodium falciparum malaria, parasitemia | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT05160363 | Feb → May 2022 | — | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01552330 | May → Oct 2012 | — | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01383109 | Jun → Sep 2011 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05974267 | Nov 2023 → Dec 2024 | Plasmodium falciparum malaria | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT05689047 | Mar 2023 → May 2024 | Plasmodium falciparum malaria | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 2 | NCT04532931 | Sep 2020 → Aug 2021 | COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04475107 | Jul 2020 → Mar 2021 | COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03814616 | Oct 2018 → Oct 2019 | Plasmodium falciparum malaria | Shin Poong Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT00331136 | Jun → Dec 2006 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 2 | NCT01594931 | Jul 2005 → Mar 2006 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04701606 | Mar 2021 → Apr 2022 | COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 35 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT06962319 | Sep 2025 → Aug 2028 expected | malaria | Liverpool School of Tropical Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT05084911 | Oct 2021 → Mar 2023 | COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04695197 | Jan 2021 → Nov 2022 | COVID-19, malaria | Liverpool School of Tropical Medicine | Completed | Missed primary |
| Phase 3 | NCT00541385 | Oct 2007 → Sep 2008 | malaria | Medicines for Malaria Venture | Completed | Met primary |
| Phase 3 | NCT04368910 | Sep 2007 → Oct 2010 | malaria | Medicines for Malaria Venture | Terminated | No outcome recorded Stop: Enrollment |
| Phase 41 trial | ||||||
| Phase 4 | NCT03726593 | Oct 2018 → Aug 2022 | Plasmodium falciparum malaria | Armed Forces Research Institute of Medical Sciences, Thailand | Unknown | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT01868438 Comparator | May → Oct 2013 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1/2 | NCT05929157 Comparator | Sep 2023 → Dec 2024 | malaria | Centre de Recherche Médicale de Lambaréné | Unknown | No outcome recorded |
| Phase 2 | NCT05291390 Comparator | Nov 2022 → Feb 2024 | acute lymphoblastic leukemia, acute myeloid leukemia | Armaceutica, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04264130 Comparator | Jul 2018 → Dec 2019 | urinary schistosomiasis | Centre de Recherche Médicale de Lambaréné | Completed | No outcome recorded |
| Phase 4 | NCT05343312 Comparator | Mar 2022 → Sep 2023 | Plasmodium falciparum malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-01-20 | Shin Poong Pharmaceutical Co. Ltd. | Results EMA에서 승인받은 국내신약16호 Pyramax® 3상 임상시험 보고서 shinpoong.co.kr ↗
그 결과, 치료율 측면에서, 피라맥스(Pyramax ® )정이 99.2%, Meflooquine + Artesunate이 97.8%(PCR corrected, at Day 28)를 보여, 피라맥스(Pyramax ® )정이 기존 치료제 복합요법(Artemisinin 계열의 약물과 타 말라리아 치료제의 병용치료요법)과 비교하여 동등이상의 효과가 있음을 입증 하였다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-01-20 | Shin Poong Pharmaceutical Co. Ltd. | EMA에서 승인받은 국내신약16호 Pyramax® 3상 임상시험 보고서 shinpoong.co.kr ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyronaridine | “artesunate-pyronaridine (AS-PY) is considered an alternative drug” PMID 40660279 ↗ Jul 202523“Pyronaridine-Artesunate(180/60mg) tablet for 3days.” NCT05084911 ↗ |
| Known as | 14C-labeled Pyronaridine | “Drug: 14C-labeled Pyronaridine” NCT01383109 ↗ |
| Known as | PND | “pyronaridine (PND)” NCT05291390 ↗ |
| Known as | PYR | “Pyramax is a pyronaridine (PYR)-artesunate (PA) combination for the treatment of uncomplicated malaria in adult and pediatric patients.” PMID 26666916 ↗ Dec 2015 |
| Known as | Pyronaridine tetraphosphate | “Pyronaridine tetraphosphate 540 mg (three tablets)” NCT05160363 ↗ |
| Route | Oral | “Oral tablets will be taken once daily for 3 consecutive days (Days 0, 1 and 2).” NCT00331136 ↗ |